Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Le Kremlin-Bicetre – page 277

3 418 clinical trials in Le Kremlin-Bicetre, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Le Kremlin-Bicetre at a glance
3 418
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 418 trials in Le Kremlin-Bicetre

Open in trial search

Marginal zone lymphoma+1

Not recruiting

Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:BeOne Medicines AG

Study on the Safety and Effects of BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BIIB080
  • Sponsor:Biogen Idec Research Limited

Hidradenitis

Not recruiting

Study on the Effects and Safety of SAR442970 for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:SAR442970
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Hodgkin's disease

Not recruiting

Study of Relatlimab and Nivolumab for Children and Young Adults with Recurrent or Refractory Hodgkin and Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Neurodermatitis

Not recruiting

Study on the Effectiveness and Safety of Ruxolitinib Cream for Patients with Prurigo Nodularis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Study of Atezolizumab and RP1 for Patients with Early-Stage Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Institut Curie

Dermatitis atopic

Not recruiting

Study on the Long-Term Safety and Effectiveness of Amlitelimab for Adults with Moderate to Severe Atopic Dermatitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Antipsychotics
  • Sponsor:Gilead Sciences Inc.

Study of Ripretinib vs Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumor with Specific KIT Exon Mutations Previously Treated with Imatinib

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ripretinib
  • Sponsor:Deciphera Pharmaceuticals Inc.

Study on Efinopegdutide and Semaglutide for Adults with Non-Alcoholic Steatohepatitis (NASH) Before Cirrhosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efinopegdutide
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Setrusumab and Bisphosphonates for Children with Osteogenesis Imperfecta

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Pamidronate Disodium
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Le Kremlin-Bicetre

What the registry says about research in the country

01 Bacterial Infections and Mycoses

Research in this area focuses on bacterial infections, especially severe ear, nose and throat diseases such as idiopathic purulent oedematous sinusitis in adults. The trials are aimed at evaluating whether treatment can improve symptoms and overall patient well-being.

  • Testing a treatment approach for persistent sinus infection
  • Assessing improvement in quality of life over time

In Kremlin Bicêtre, this work reflects a practical effort to better manage chronic ENT infection-related complaints.

02 Cardiovascular Diseases

Clinical research here also covers cardiovascular disease in patients hospitalized for septic shock with tachycardia and hypercontractility. The main goal is to evaluate whether controlling heart rate may help improve survival and clinical outcomes.

  • Studying a heart-rate-lowering strategy in septic shock
  • Comparing outcomes against standard care

These trials are designed to clarify whether better cardiovascular support can reduce risk in critically ill patients.

03 Otorhinolaryngologic Diseases

Another key research focus is otorhinolaryngology, with attention on sinusitis and related ENT disorders. The studies are looking at treatment effectiveness and changes in patient-reported symptoms during follow-up.

  • Measuring symptom relief in sinus disease
  • Tracking changes in disease-specific quality of life

This area highlights efforts to improve everyday functioning for patients living with ongoing nasal and sinus problems.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.